Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Assessing NLRP3 Inflammasome Activation by Nanoparticles.

Bhawna Sharma1, Christopher B McLeland1, Timothy M Potter1

  • 1Cancer Research Technology Program, Nanotechnology Characterization Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, P.O. Box B, Frederick, MD, 21702, USA.

Methods in Molecular Biology (Clifton, N.J.)
|October 18, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An interesting Case series of Actinomycosis: An imposter in many chronic infectious diseases from a tertiary care hospital, New Delhi, India.

Indian journal of medical microbiology·2026
Same author

Serotonergic Regulation of Nicotine Addiction: Receptor-specific Mechanisms and Therapeutic Strategies.

Current neurovascular research·2026
Same author

Advancement in Sodium Alginate-Based Drug Delivery Systems: Applications and Future Prospects.

AAPS PharmSciTech·2026
Same author

Chromatographic Estimation of Curcumin and Parthenolide Using a Validated RP-HPLC Method.

Current drug research reviews·2026
Same author

Plant Protein Essentials: From Source to Production.

Current protein & peptide science·2026
Same author

Leveraging Existing Knowledge for Drug Repurposing: A Rational Approach to Addressing Unmet Medical Needs.

Reviews on recent clinical trials·2026

Nanoparticles can activate the NLRP3 inflammasome, initiating an immune response. Monitoring IL-1β release helps predict nanoparticle effects for vaccine or drug development.

Area of Science:

  • Immunology
  • Nanotechnology
  • Cell Biology

Background:

  • The NLRP3 inflammasome is crucial for innate immunity against pathogens and environmental triggers.
  • Nanoparticles are widely used in medicine as vaccine adjuvants and drug delivery systems.
  • Nanoparticle administration can elicit immune responses, beneficial for vaccines but potentially toxic for drug delivery.

Purpose of the Study:

  • To establish a protocol for monitoring NLRP3 inflammasome activation by nanoparticles.
  • To use IL-1β release as a biomarker for NLRP3 inflammasome activation.
  • To evaluate the potential of nanoparticles in vaccine and drug delivery applications.

Main Methods:

  • Utilizing PMA-primed THP-1 cells, a human monocytic cell line, as a model system.
Keywords:
IL-1βInflammasomeNLRP3NanoparticlesTHP-1

Related Experiment Videos

  • Monitoring the release of IL-1β cytokine as an indicator of inflammasome activation.
  • Investigating nanoparticle-induced inflammatory responses.

    • Main Results:

    • The study outlines a method to detect IL-1β release, signifying NLRP3 inflammasome activation.
    • Different nanoparticles have been shown to induce varying levels of NLRP3 inflammasome activation.
    • IL-1β release serves as a reliable marker for nanoparticle-mediated immune responses.

    Conclusions:

    • Evaluating nanoparticle-induced NLRP3 inflammasome activation is key to optimizing vaccine adjuvants and mitigating drug delivery immunotoxicity.
    • This protocol provides a framework for assessing the immunomodulatory potential of nanoparticles.
    • Understanding these inflammatory pathways is essential for advancing nanomedicine.